Marstacimab

Marstacimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTFPI
Clinical data
Trade namesHympavzi
Other namesPF-06741086, marstacimab-hncq
AHFS/Drugs.comHympavzi
License data
Routes of
administration		Intravenous
Drug classTissue factor pathway inhibitor (TFPI)
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6304H9766N1678O2006S44
Molar mass142569.85 g·mol−1

Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B.[1][4][2] It is a tissue factor pathway inhibitor (TFPI) antagonist.[4] It was developed by Pfizer.[5] Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor.[4] This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated.[4] This is expected to reduce or prevent the frequency of bleeding episodes.[4]

The most common side effects include injection site reactions, headache, and itching (pruritis).[4]

Marstacimab was approved for medical use in the United States in October 2024,[4] and in the European Union in November 2024.[3]

  1. ^ a b "Hympavzi- marstacimab-hncq injection, solution". DailyMed. 5 November 2024. Retrieved 11 November 2024.
  2. ^ a b Cite error: The named reference Hympavzi EPAR was invoked but never defined (see the help page).
  3. ^ a b "Hympavzi PI". Union Register of medicinal products. 19 November 2024. Retrieved 21 November 2024.
  4. ^ a b c d e f g Cite error: The named reference FDA PR 20241011 was invoked but never defined (see the help page).
  5. ^ "FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B". Pfizer (Press release). 9 December 2023. Retrieved 21 September 2024.